Physician profile
Michael J Janowicz
NPI 1285632430
$1,757.78
in general payments reported to CMS, 2019-2025
19 companies · $618 in 2025
The $618 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.68 · 2020: $93.53 · 2021: $125 · 2022: $329 · 2023: $204 · 2024: $310 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079 · Entertainment: $53.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.74 |
| Entertainment | $53.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $555.20 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Abbvie INC. | $227.72 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $198.95 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $128.70 | 2024-2025 | Xdemvy |
| Lensar, INC. | $86.46 | 2024 | Lensar Laser System |
| Thea Pharma INC. | $82.87 | 2024-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $73.65 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $72.63 | 2019-2020 | |
| Optos, INC. | $53.08 | 2024-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $46.90 | 2022-2025 | Vyzulta |
| Carl Zeiss Meditec USA, INC. | $42.23 | 2023 | Humphrey Hfa |
| Sun Pharmaceutical Industries INC. | $35.84 | 2023-2025 | Cequa |
| Amgen INC. | $34.82 | 2025 | Tepezza |
| Allergan, INC. | $34.72 | 2021-2022 | |
| Rxsight INC | $21.03 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $20.17 | 2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $18.20 | 2022 | |
| Shire North American Group INC | $13.53 | 2019 | |
| Tearlab Corp | $11.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Janowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.